Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions highlight the promising results of the epicutaneous immunotherapy trial, emphasizing that '67% of 1-3 year olds with peanut allergy experienced desensitization compared to 33.5% with placebo.' Phrases like 'good news for kids and parents' and references to the study as a 'game changer' illustrate the optimistic tone and urgency around advancing treatment options, reflecting a strong collective hope for better management of peanut allergies.
Most discussions express support for the findings of the publication, reflecting a general consensus on the benefits of the peanut patch.
There is a strong interest in the implications of the research, particularly regarding its potential to improve treatment options for peanut allergies in young children.
While several posts express initial reactions or summarize results, a number of discussions delve into the details of the study, indicating moderate depth of engagement.
Many contributors believe the study represents a significant advancement in peanut allergy treatment, suggesting it could lead to major improvements in care for affected children.
Treatments for peanut allergy are not approved for children <4 years of age. However, treatment at younger ages may be more effective than at older ages. Read the EPITOPE trial Research Summary: https://t.co/USk6HBI9Qh
Original Article: Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy (EPITOPE trial) https://t.co/USk6HBIHFP #pediatrics https://t.co/BOlvszotNV
Goda nyheter ett plåster för desentisering av Jordnötsallergi är påväg för barn. I studien svarade dubbelt så många barn under 4 års ålder på plåstret jämfört med placebo. https://t.co/bDzKd7cDgj
Read "Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy," the NEJM Original Article referenced in this @statnews article: https://t.co/USk6HBI9Qh https://t.co/S3VAGmTdZN
3. Phase 3 Trial of Epicutaneous #Immunotherapy in Toddlers with Peanut Allergy https://t.co/USk6HBIHFP #pediatrics View all trending articles: https://t.co/ORZDa6ntRn https://t.co/hVwDnLMTQ3
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy @NEJM #MedEd #MedTwitter #peanut #allergy https://t.co/iwCt9nsbiK https://t.co/eK7ZjE43X7
No approved treatment for peanut allergy exists for children under 4. This video discusses a trial involving 362 toddlers aged 1 to 3, focusing on the peanut patch's safety and efficacy. Results showed a positive…
This week features news on food innovation, including the use of GMOs in agriculture to address organic farming's limitations. Additionally, we explore a Phase 3 trial of a peanut patch aimed at toddlers, showing…
1-3歳にピーナツの経皮パッチを使用することでピーナツアレルギーが減少するというRCT 毎日食べさせるよりもかなりハードルが低いので、普及するといいですね https://t.co/xWPwLt91Hi
RT @VedouKeZdravi: Zdroj: Greenhawt M, Sindher SB, Wang J, et al. Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Aller…
RT @DBVTechnologies: Our EPITOPE Phase 3 trial, evaluating our investigational Viaskin Peanut, found epicutaneous immunotherapy superior to…
Our EPITOPE Phase 3 trial, evaluating our investigational Viaskin Peanut, found epicutaneous immunotherapy superior to placebo in desensitizing to peanuts & increasing the peanut dose required to trigger allergy symptoms. Read the trial findings in @NEJM: https://t.co/Jyg98HMfYy https://t.co/eyHVlkMZl8
RT @Method_Focused: 今週（6/21 18:00）の #メソッドジャーナルクラブ では、NEJMで報告されたピーナッツアレルギー研究を扱います。 中間事象を具体的にどのように取り入れたか詳しく見ていきます。 Phase 3 Trial of Epicuta…
RT @Aller_MD: #Immunotherapy with #Peanut Patch in Toddlers. Quick Take. NEJM https://t.co/owuoqrIy4w https://t.co/p4V9ysFkbu
https://t.co/afbtgtYMjV Read carefully. Oh my.....
RT @Asfyxi: Goda nyheter ett plåster för desentisering av Jordnötsallergi är påväg för barn. I studien svarade dubbelt så många barn under…
RT @Aller_MD: In a phase 3 trial involving children 1 to 3 years of age with #peanut #allergy, epicutaneous #immunotherapy for 12 months wa…
RT @Aller_MD: In a phase 3 trial involving children 1 to 3 years of age with #peanut #allergy, epicutaneous #immunotherapy for 12 months wa…
RT @Aller_MD: In a phase 3 trial involving children 1 to 3 years of age with #peanut #allergy, epicutaneous #immunotherapy for 12 months wa…
RT @Aller_MD: In a phase 3 trial involving children 1 to 3 years of age with #peanut #allergy, epicutaneous #immunotherapy for 12 months wa…
RT @Asfyxi: Goda nyheter ett plåster för desentisering av Jordnötsallergi är påväg för barn. I studien svarade dubbelt så många barn under…
In a phase 3 trial involving children 1 to 3 years of age with #peanut #allergy, epicutaneous #immunotherapy for 12 months was superior to placebo in desensitizing children to peanuts and increasing the peanut dose that triggered allergic symptoms. https://t.co/NURYFBql33 https://t.co/Jt1bcgSFzF
RT @Asfyxi: Goda nyheter ett plåster för desentisering av Jordnötsallergi är påväg för barn. I studien svarade dubbelt så många barn under…
Goda nyheter ett plåster för desentisering av Jordnötsallergi är påväg för barn. I studien svarade dubbelt så många barn under 4 års ålder på plåstret jämfört med placebo. https://t.co/bDzKd7cDgj
ピーナッツアレルギーをパッチで治す 1−3才児でも有効 かなり安全 5月の論文 ヴィデオあり Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy | NEJM https://t.co/NPkB5LSrkB
RT @Aller_MD: #Immunotherapy with #Peanut Patch in Toddlers. Quick Take. NEJM https://t.co/owuoqrIy4w https://t.co/p4V9ysFkbu
RT @Aller_MD: #Immunotherapy with #Peanut Patch in Toddlers. Quick Take. NEJM https://t.co/owuoqrIy4w https://t.co/p4V9ysFkbu
RT @Aller_MD: #Immunotherapy with #Peanut Patch in Toddlers. Quick Take. NEJM https://t.co/owuoqrIy4w https://t.co/p4V9ysFkbu
RT @Aller_MD: #Immunotherapy with #Peanut Patch in Toddlers. Quick Take. NEJM https://t.co/owuoqrIy4w https://t.co/p4V9ysFkbu
#Immunotherapy with #Peanut Patch in Toddlers. Quick Take. NEJM https://t.co/owuoqrIy4w https://t.co/p4V9ysFkbu
Here's the journal article: https://t.co/xaP0VWqKk0
RT @Method_Focused: 今週（6/21 18:00）の #メソッドジャーナルクラブ では、NEJMで報告されたピーナッツアレルギー研究を扱います。 中間事象を具体的にどのように取り入れたか詳しく見ていきます。 Phase 3 Trial of Epicuta…
今週（6/21 18:00）の #メソッドジャーナルクラブ では、NEJMで報告されたピーナッツアレルギー研究を扱います。 中間事象を具体的にどのように取り入れたか詳しく見ていきます。 Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy | NEJM https://t.co/6Hjm3SreVA
RT @NEJM: 3. Phase 3 Trial of Epicutaneous #Immunotherapy in Toddlers with Peanut Allergy https://t.co/USk6HBIHFP #pediatrics View all tre…
Zdroj: Greenhawt M, Sindher SB, Wang J, et al. Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy. N Engl J Med. 2023 May 11;388(19):1755-1766.
The newest episode of the 2 Minute Medicine #Podcast is out! We begin this episode by discussing our article of the week comes from the @NEJM and is entitled “Phase 3 Trial of Epicutaneous #Immunotherapy in #Toddlers with #Peanut #Allergy“. In the second half of our episode, we https://t.co/x41wxeCwHI
Patches: A Path to Peanut Allergy Relief for Young Children? https://t.co/JLnn8MFxfs
Positive results from a phase 3 global clinical trial testing https://t.co/HPrM4Ofm8T
→続き) 小児の
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy https://t.co/HjoFbdQpbK ピーナッツアレルギー幼児を対象とした表皮免疫療法の第3相試験（二重盲検ランダム化比較試験）
Read the full story here - ⬇️⬇️⬇️ https://t.co/Vc6AqL8Had Read all NHD Latest News stories here ⬇️⬇️⬇️ https://t.co/ItEC3CQ3mh
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy | NEJM https://t.co/5KFpyMUsrV
Hilfe für Kinder mit Erdnussallergie in Sicht. Studie mit #UKF-Beteiligung zeigt: Pflaster mit Erdnussprotein können das Risiko schwerer allergischer Reaktionen senken ➡️ https://t.co/LQFPm2pvmM Die Ergebnisse zum Nachlesen @NEJM ➡️ https://t.co/W47JlqhF0S https://t.co/52OFx2at7y
N Engl J Med 2023; 388:1755-1766 DOI: 10.1056/NEJMoa2212895 https://t.co/GRcLpS8x2h
RT @alfonso_casi: En este ensayo con niños de 1 a 3 años y alergia al maní, la inmunoterapia epicutánea durante 12 meses fue superior al pl…
RT @NEJM: 3. Phase 3 Trial of Epicutaneous #Immunotherapy in Toddlers with Peanut Allergy https://t.co/USk6HBIHFP #pediatrics View all tre…
RT @NEJM: 3. Phase 3 Trial of Epicutaneous #Immunotherapy in Toddlers with Peanut Allergy https://t.co/USk6HBIHFP #pediatrics View all tre…
RT @NEJM: 3. Phase 3 Trial of Epicutaneous #Immunotherapy in Toddlers with Peanut Allergy https://t.co/USk6HBIHFP #pediatrics View all tre…
3. Phase 3 Trial of Epicutaneous #Immunotherapy in Toddlers with Peanut Allergy https://t.co/USk6HBIHFP #pediatrics View all trending articles: https://t.co/ORZDa6ntRn https://t.co/hVwDnLMTQ3
RT @ATSPeds: Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy | NEJM https://t.co/5GTY3ls7hZ TA: @msupedspulm #p…
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy | NEJM https://t.co/5GTY3ls7hZ TA: @msupedspulm #pedspulm
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy | NEJM https://t.co/B2mn1BLm4a
RT @almucastro01: Buenas noticias para los alérgicos al cacahuete: https://t.co/RBCxThbJhG https://t.co/uvjIdXA85J
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy | NEJM https://t.co/kEVnZZhcnD
En este ensayo con niños de 1 a 3 años y alergia al maní, la inmunoterapia epicutánea durante 12 meses fue superior al placebo para desensibilizar a los niños al maní y aumentar la dosis de maní que desencadenó los síntomas alérgicos. https://t.co/uOVK3lFv9E
Buenas noticias para los alérgicos al cacahuete: https://t.co/RBCxThbJhG https://t.co/uvjIdXA85J
RT @NEJM: Original Article: Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy (EPITOPE trial) https://t.co/USk6HB…
RT @SickKidsNews: The New England Journal of Medicine (@NEJM) has published data from a Phase 3 EPITOPE trial of epicutaneous #immunotherap…
RT @SickKidsNews: The New England Journal of Medicine (@NEJM) has published data from a Phase 3 EPITOPE trial of epicutaneous #immunotherap…
RT @Pon_yurublog: NEJMの論文で、ピーナッツ
RT @Pon_yurublog: NEJMの論文で、ピーナッツ
RT @Pon_yurublog: NEJMの論文で、ピーナッツ
RT @Pon_yurublog: NEJMの論文で、ピーナッツ
NEJMの論文で、ピーナッツ
RT @daniel_kraft: Wearing a peanut allergen patch for 12 months desensitized toddlers with mild allergies to peanuts, meaning they could t…
RT @SickKidsNews: The New England Journal of Medicine (@NEJM) has published data from a Phase 3 EPITOPE trial of epicutaneous #immunotherap…
RT @SickKidsNews: The New England Journal of Medicine (@NEJM) has published data from a Phase 3 EPITOPE trial of epicutaneous #immunotherap…
RT @SickKidsNews: The New England Journal of Medicine (@NEJM) has published data from a Phase 3 EPITOPE trial of epicutaneous #immunotherap…
RT @SickKidsNews: The New England Journal of Medicine (@NEJM) has published data from a Phase 3 EPITOPE trial of epicutaneous #immunotherap…
The New England Journal of Medicine (@NEJM) has published data from a Phase 3 EPITOPE trial of epicutaneous #immunotherapy in peanut allergic children 1-3 years old. #SKResearch #SKFoodAllergyAnaphylaxisProgram #AllergyMonth Learn more ⤵️ https://t.co/StumNswkjc
RT @medical_xpress: Skin patch could help ease #peanut #allergy in toddlers @nejm https://t.co/2d7GXqKHc1 https://t.co/3AkdcDdKUE
@mmimicro_inc @prsjournal @salkinstitute @CellCellPress 5/ Phase 3 randomized multicenter trial for an allergy-treating skin patch (ie, epicutaneous immunotherapy) shows promising results, with superior results to placebo, published in @nejm https://t.co/hZMB5G48kr https://t.co/m2CS7OoeaT
RT @NEJM: Treatments for peanut allergy are not approved for children <4 years of age. However, treatment at younger ages may be more effec…
RT @NEJM: Treatments for peanut allergy are not approved for children <4 years of age. However, treatment at younger ages may be more effec…
RT @NEJM: Treatments for peanut allergy are not approved for children <4 years of age. However, treatment at younger ages may be more effec…
RT @NEJM: Treatments for peanut allergy are not approved for children <4 years of age. However, treatment at younger ages may be more effec…
RT @DBVTechnologies: #ICYMI, @NEJM recently published our Phase 3 EPITOPE trial evaluating our investigational Viaskin Peanut in toddlers.…
RT @NEJM: Treatments for peanut allergy are not approved for children <4 years of age. However, treatment at younger ages may be more effec…
#ICYMI, @NEJM recently published our Phase 3 EPITOPE trial evaluating our investigational Viaskin Peanut in toddlers. Read the full publication: https://t.co/DTUWVcEq3X https://t.co/3J8PAZtzig
RT @NEJM: Treatments for peanut allergy are not approved for children <4 years of age. However, treatment at younger ages may be more effec…
https://t.co/KCfWgaeatL
RT @NEJM: Treatments for peanut allergy are not approved for children <4 years of age. However, treatment at younger ages may be more effec…
RT @NEJM: Treatments for peanut allergy are not approved for children <4 years of age. However, treatment at younger ages may be more effec…
RT @NEJM: Treatments for peanut allergy are not approved for children <4 years of age. However, treatment at younger ages may be more effec…
RT @NEJM: Treatments for peanut allergy are not approved for children <4 years of age. However, treatment at younger ages may be more effec…
RT @NEJM: Treatments for peanut allergy are not approved for children <4 years of age. However, treatment at younger ages may be more effec…
RT @NEJM: Treatments for peanut allergy are not approved for children <4 years of age. However, treatment at younger ages may be more effec…
Treatments for peanut allergy are not approved for children <4 years of age. However, treatment at younger ages may be more effective than at older ages. Read the EPITOPE trial Research Summary: https://t.co/USk6HBI9Qh
NEJM ピーナッツパッチの経皮免疫療法の検証 第3層試験(治療効果と安全性の検証) end point 12ヶ月経過時点での治療効果 介入群、治療できた割合は高いが有害事象がやや多い。 まだ大まかにしか読めてませんので、詳細は原著を参照。#アレルギー #救急 #こども https://t.co/PZbTTlK2XQ
RT @NEJM: Original Article: Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy (EPITOPE trial) https://t.co/USk6HB…
RT @NEJM: Original Article: Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy (EPITOPE trial) https://t.co/USk6HB…
ルギーがなくなった）のに対し、偽薬群の118人の幼児では1/3しか脱感作しませんでした。治験に参加した幼児4人は、パッチに関連したアナフィラキシー反応を経験、1人は治験を中止、他の3人は再反応することなく治療を再開しました。https://t.co/vGoHrwXID2
RT @imedverse: Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy @NEJM #MedEd #MedTwitter #peanut #allergy htt…
RT @NEJM: Original Article: Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy (EPITOPE trial) https://t.co/USk6HB…
RT @imedverse: Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy @NEJM #MedEd #MedTwitter #peanut #allergy htt…
RT @imedverse: Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy @NEJM #MedEd #MedTwitter #peanut #allergy htt…
RT @imedverse: Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy @NEJM #MedEd #MedTwitter #peanut #allergy htt…
RT @imedverse: Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy @NEJM #MedEd #MedTwitter #peanut #allergy htt…
RT @imedverse: Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy @NEJM #MedEd #MedTwitter #peanut #allergy htt…
RT @imedverse: Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy @NEJM #MedEd #MedTwitter #peanut #allergy htt…
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy @NEJM #MedEd #MedTwitter #peanut #allergy https://t.co/iwCt9nsbiK https://t.co/eK7ZjE43X7
RT @NEJM: Original Article: Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy (EPITOPE trial) https://t.co/USk6HB…
RT @NEJM: Original Article: Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy (EPITOPE trial) https://t.co/USk6HB…
Original Article: Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy (EPITOPE trial) https://t.co/USk6HBIHFP #pediatrics https://t.co/BOlvszotNV
RT @JhKmann: great to see that Katharina Blümchen from our department at @goetheuni and @UK_Frankfurt was part of this groundbreaking study…
RT @NEJM: Read "Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy," the NEJM Original Article referenced in this…
great to see that Katharina Blümchen from our department at @goetheuni and @UK_Frankfurt was part of this groundbreaking study, which will make a huge difference for people with #peanuts #allergies, which is the most common type of food allergy. https://t.co/WH5sU32JBO
Epicutaneous peanut immunotherapy (IT) desensitises 67% of 1-3 year olds with peanut allergy. But placebo (read: natural history) works in 34%. Why commit children to lifelong IT at an age when they still have a 1 in 3 chance of outgrowing the allergy?
RT @AllergyKidsDoc: We’ve seen promising safety and efficacy data for the peanut patch in children and adolescents… Great to see similar b…
Fascinating to see how allergists are successfully using desensitization. An epicutaneous patch, containing only micrograms of peanut protein, significantly reduces allergic reactions in toddlers. https://t.co/mROCQaO75c
May is awareness month for those affected by #Allergies and it's great to see continued research into novel therapies! Keep in mind that this was a small, placebo controlled study, but promising results and more data to come I'm sure! @NEJM https://t.co/ikGXAyBGjx #foodallergies https://t.co/mt7NDGpA5m
RT @Aller_MD: Phase 3 Trial of #Epicutaneous #Immunotherapy in Toddlers with #Peanut #Allergy | NEJM https://t.co/NURYFBql33 https://t.co/3…
RT @Aller_MD: Phase 3 Trial of #Epicutaneous #Immunotherapy in Toddlers with #Peanut #Allergy | NEJM https://t.co/NURYFBql33 https://t.co/3…
RT @Aller_MD: Phase 3 Trial of #Epicutaneous #Immunotherapy in Toddlers with #Peanut #Allergy | NEJM https://t.co/NURYFBql33 https://t.co/3…
RT @Aller_MD: Phase 3 Trial of #Epicutaneous #Immunotherapy in Toddlers with #Peanut #Allergy | NEJM https://t.co/NURYFBql33 https://t.co/3…
RT @KamiMasahiro: 今週のNEJMが小児のピーナツアレルギーに対する免疫療法の好結果を報じています。これは日本の子供たちにも、いいニュースです。 https://t.co/EaC8vJlr2r
RT @NEJM: Read "Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy," the NEJM Original Article referenced in this…
RT @Aller_MD: Phase 3 Trial of #Epicutaneous #Immunotherapy in Toddlers with #Peanut #Allergy | NEJM https://t.co/NURYFBql33 https://t.co/3…
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy Epicutaneous immunotherapy for 12 months was superior to placebo in desensitizing children to peanuts and increasing the peanut dose that triggered allergic symptoms https://t.co/2Xau7Pdy01
RT @NEJM: Read "Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy," the NEJM Original Article referenced in this…
RT @medical_xpress: Skin patch could help ease #peanut #allergy in toddlers @nejm https://t.co/2d7GXqKHc1 https://t.co/3AkdcDdKUE
RT @medical_xpress: Skin patch could help ease #peanut #allergy in toddlers @nejm https://t.co/2d7GXqKHc1 https://t.co/3AkdcDdKUE
RT @medical_xpress: Skin patch could help ease #peanut #allergy in toddlers @nejm https://t.co/2d7GXqKHc1 https://t.co/3AkdcDdKUE
RT @Aller_MD: Phase 3 Trial of #Epicutaneous #Immunotherapy in Toddlers with #Peanut #Allergy | NEJM https://t.co/NURYFBql33 https://t.co/3…
Phase 3 Trial of #Epicutaneous #Immunotherapy in Toddlers with #Peanut #Allergy | NEJM https://t.co/NURYFBql33 https://t.co/3FsvXkOLOH
RT @medical_xpress: Skin patch could help ease #peanut #allergy in toddlers @nejm https://t.co/2d7GXqKHc1 https://t.co/3AkdcDdKUE
RT @medical_xpress: Skin patch could help ease #peanut #allergy in toddlers @nejm https://t.co/2d7GXqKHc1 https://t.co/3AkdcDdKUE
RT @medical_xpress: Skin patch could help ease #peanut #allergy in toddlers @nejm https://t.co/2d7GXqKHc1 https://t.co/3AkdcDdKUE
RT @medical_xpress: Skin patch could help ease #peanut #allergy in toddlers @nejm https://t.co/2d7GXqKHc1 https://t.co/3AkdcDdKUE
RT @medical_xpress: Skin patch could help ease #peanut #allergy in toddlers @nejm https://t.co/2d7GXqKHc1 https://t.co/3AkdcDdKUE
RT @medical_xpress: Skin patch could help ease #peanut #allergy in toddlers @nejm https://t.co/2d7GXqKHc1 https://t.co/3AkdcDdKUE
Skin patch could help ease #peanut #allergy in toddlers @nejm https://t.co/2d7GXqKHc1 https://t.co/3AkdcDdKUE
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy | NEJM https://t.co/lBEv3cpzrU #allergy #peanuts #peanutallergy #toddlers #patch #medicine #health #research
RT @GCHAllergyChief: Proud to say that our Center for Food Allergy team lead by Dr Katherine Tuttle also contributed for this study. Phase…
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy | NEJM https://t.co/IAjHg4AAsy
RT @NEJM: Read "Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy," the NEJM Original Article referenced in this…
RT @NEJM: Read "Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy," the NEJM Original Article referenced in this…
RT @NEJM: Read "Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy," the NEJM Original Article referenced in this…
RT @NEJM: Read "Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy," the NEJM Original Article referenced in this…
Read "Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy," the NEJM Original Article referenced in this @statnews article: https://t.co/USk6HBI9Qh https://t.co/S3VAGmTdZN
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy | NEJM https://t.co/D8vJZuMfeI
RT @FoodAllergyNCBI: Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy https://t.co/N3FSPVCmiZ
RT @crisrijue: Avanzando en #inmunoterapia por vía epicutánea, avances para la #alergiaalimentos #alergiacacahuete Phase 3 Trial of Epicuta…
Skin as a modulator of allergies - good news for kids and parents Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy | NEJM https://t.co/NDbq4WNylv
Avanzando en #inmunoterapia por vía epicutánea, avances para la #alergiaalimentos #alergiacacahuete Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy | NEJM https://t.co/ocWZPeMsRZ
RT @GCHAllergyChief: Proud to say that our Center for Food Allergy team lead by Dr Katherine Tuttle also contributed for this study. Phase…
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy https://t.co/AHx6zX2kC2 https://t.co/XQSbEXO2R5
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy https://t.co/N3FSPVCmiZ
Proud to say that our Center for Food Allergy team lead by Dr Katherine Tuttle also contributed for this study. Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy | NEJM https://t.co/rYIMEyJhq7 @HaltermanJill @GCHPedsChair @FoodAllergyMD @ATLergist
Peanut allergy- Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy | NEJM https://t.co/ch7MqS9wu9
NEJM: Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy https://t.co/nNUDrOAC7j
Matthew Greenhawt: Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy https://t.co/wlRdCQFj5U
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy $DBV $DBVT | NEJM https://t.co/fcfyChXHUF